MVIP

MEDICON VILLAGE INVESTOR PANEL

AUTUMN BATCH 2025

STRATEGIC CAPITAL. EXPERT GUIDANCE. LIFE-CHANGING LIFE SCIENCE.

MVIP

The Medicon Village Investor Panel (MVIP) is a strategic initiative by Medicon Village designed to strengthen the financial ecosystem for life science companies by connecting them with crucial capital and expert investor support.

MEDICON VILLAGE

Medicon Village is Scandinavia's largest life science park. We're here to foster innovation and advance collaboration to support your research and business.

Medicon Village encompasses the entire life science spectrum, from research in key fields such as biotech, pharma, and medtech to members specialising in the full healthcare chain – from prevention and diagnostics to treatment and care. Together, Medicon Village provides most of the services and equipment needed for life science research and business, including pre-clinical and biobank facilities, either on-site or within walking distance in the Lund Innovation District.

A word from Medicon Village

Access to capital is one of the most pressing challenges for life science companies. In a sector where development is complex and capital-intensive, strong investor relationships are essential – not only for funding growth, but also for gaining strategic insights, operational expertise, and access to critical networks.

To help meet this need, we have launched the Medicon Village Investor Panel (MVIP) in collaboration with Markus Neuding, corporate finance expert and owner of Sedermera Corporate Finance. With Markus' deep experience and established investor network, MVIP offers our member companies a structured and strategic pathway to strengthen their investment readiness.

What sets MVIP apart is its long-term approach. Rather than focusing on individual funding rounds, the initiative helps companies prepare for sustainable growth by engaging with investors across multiple capital stages and receiving actionable feedback.

At Medicon Village, we are committed to supporting companies throughout their journey. MVIP is a reflection of that commitment, and serves as a concrete step toward building a stronger, more connected life science ecosystem.

We look forward to this very first MVIP session, and we hope that this will lead to stronger relationships and concrete financing opportunities for participating investors and companies alike.

Petter Hartman, CEO
Medicon Village Innovation

Sarah Lidé, Deputy CEO
Medicon Village Innovation

About MVIP

Medicon Village Investor Panel (MVIP) is a strategic initiative designed to strengthen the financial ecosystem for life science companies by connecting them with crucial capital and expert investor support.

This program will connect Medicon Village companies with a curated panel of experienced investors to help accelerate growth and innovation in the life science sector.

Led by corporate finance expert Markus Neuding, MVIP offers a unique opportunity for companies to pitch their businesses to a distinguished panel of investors with diverse backgrounds in life science funding.

By bringing together professionals with diverse experience in life science funding, MVIP will provide access to new capital and unlock valuable expertise, strategic insights, and networking opportunities essential for growth and success in this complex sector.

The team behind MVIP

Markus Neuding Owner, Sedermera Corporate Finance

Markus is a former lawyer and seasoned entrepreneur with a background as Executive Vice President of Spotlight Group. He recently acquired Sedermera Corporate Finance, one of the Nordic region's most active advisory firms within capital raising and M&A for growth companies, where he now serves as owner and principal. Markus has founded and built several companies and brings deep expertise in entrepreneurship, business development, and exits. As the coordinator of the Medicon Village Investor Panel, he also serves as a permanent member of the panel.

markus.neuding@sedermera.se

Sarah Lidé Deputy CEO, Medicon Village Innovation

Sarah has two decades' worth of experience in management consulting and ecosystem building within the public sector, healthcare, and life science sectors. She has held a variety of international roles involving leading and facilitating strategic processes, understanding macro and industry trends and their implications for business, and driving multi-stakeholder engagement. In her current position as Deputy CEO at Medicon Village Innovation, she leads various life science-related strategic initiatives on behalf of Medicon Village to support companies in the areas of commercialisation, capital access, and competence supply, including the Medicon Village Investor Panel.

sarah.lide@mediconvillage.se

Francesco Bez Ph.D. Innovation Manager, Medicon Village Innovation

Francesco is Innovation Manager at Medicon Village, where he leads strategic initiatives in the life science sector. He holds a Ph.D. in Neuroscience and Biomedicine and brings a solid background in both preclinical research and marketing. Over the past decade, Francesco has held various roles within Medicon Village-based companies, contributing to their growth and the development of their service offerings. In his current role, he is actively engaged in several EU-funded programs and regional initiatives, as well as strategic collaborations with big pharma companies and investor networks.

francesco.bez@mediconvillage.se

Solutio™ by MedVasc

MedVasc AB

MEDTECH

Paindrainer

Paindrainer

HEALTHTECH

PHARMNOVO Innovation in pain relief

PharmNovo

PHARMA

RESPIRATORIUS

Respiratorius

PHARMA

RECCAN

Reccan AB

DIAGNOSTICS

STRIKE Pharma

Strike Pharma

PHARMA | BIOTECH

Suturion®

Suturion

MEDTECH

targinta

Targinta

PHARMA

Bengt Julander
Chairman at Linc AB

Erika Henriksson
Partner at EQT

Elin Almstedt
Principal at Navigare Ventures

Hugo Mörse
Partner at Bonit Capital and Managing Director of Leksell Social Ventures

Christer Fåhræus
Partner and CEO at Fåhraeus Startup and Growth

Maria Tell
COO / Investment Director at Segulah Medical Acceleration

Lovisa Backemar
Principal at Eir Ventures

Sebastian Hodel
CEO and CIO at Gainbridge Capital

Andreas Grape
CEO and Co-founder at Nordic Angels

Ann-Charlotte Beckman
Co-founder at Life Science Invest

Johan Kördel
Managing Partner at Sound Bioventures

Markus Neuding
The coordinator of the Medicon Village Investor Panel

PROGRAM OCTOBER 8

08.30–09.00	**Welcome & breakfast** Light breakfast and networking
09.00–09.15	Introduction from Medicon Village

Morning session:
Company pitches – part 1

09.15–09.50	MedVasc AB – Medtech
09.50–10.25	Paindrainer – Healthtech
10.25–10.45	**Coffee break & mingling**
10.45–11.20	PharmNovo – Pharma
11.20–11.55	Respiratorius – Pharma
12.00–13.00	**Lunch break**

Afternoon session:
Company pitches – part 2

13.00–13.35	Reccan AB – Diagnostics
13.35–14.10	Strike Pharma – Pharma / Biotech
14.10–14.30	**Coffee break & mingling**
14.30–15.05	Suturion – Medtech
15.05–15.40	Targinta – Pharma
15.40–16.30	**Closing remarks & networking** Final reflections and mingling

Solutio™
by MedVasc

MedVasc

MedVasc have developed Solutio - a catheter system designed for targeted, minimal-invasive deployment of tumescent local anesthesia, improving thermal ablation, golden standard treatment of venous insufficiency/varicose veins. The Solutio catheter system introduces a new category that allows for pain-free and precise delivery, replacing a painful and inefficient procedure.

Solutio™ is compatible with both RF & Laser fibers and is by definition improving the existing golden standard treatment procedure, giving the market leaders of endothermal treatment fibers a competitive advantage and securing future dominance compared to new treatment methods.

medvasc.se

FIELD
Medtech

DATE OF INCORPORATION
2013

STOCK MARKET LISTING
No

MATURITY
Commercial stage

PRODUCT ON THE MARKET?
Within the next 12 months

AMOUNT THEY WISH TO RAISE WITH MVIP
25 MSEK

HOW THEY INTEND TO USE THE FUNDS RAISED
Takes us to FDA clearance, limited market release (100 first units) and is a possible point for an Exit

Cathrin Johansson

CEO

Cathrin is a former top athlete and has held several leading roles in both private and public organizations. Before joining MedVasc she worked with Ignite Sweden, where she successfully contributed to catalyzing commercial collaborations between startups and large international corporations/public organizations.

Prior to Ignite, she held positions as Head of AWA Innovation and Group Communication Manager at AWA. She likes freestyle skiing and has competed in the halfpipe world cup.

cathrin.johansson@medvasc.se

NOTES

Paindrainer

Paindrainer is a Digital Therapeutics company that has developed a digital self-management device for individuals living with persistent pain. The device is powered by a proprietary artificial neural network functioning as a coach for the patient to align daily activities and to alleviate pain. The device has several successful clinical trials to show and the core is protected by an EP-granted patent with applications under evaluation in other markets.

The company is currently fully focused on developing the 3rd generation device, named Relivra, where an LLM (Large Language model) will interact with the current ANN. This to support better patient engagement and educational support.

paindrainer.com

FIELD
Healthtech

DATE OF INCORPORATION
2018

STOCK MARKET LISTING
No

MATURITY
Growth stage

PRODUCT ON THE MARKET?
We currently have a product/candidate on the market

AMOUNT THEY WISH TO RAISE WITH MVIP
25 MSEK

HOW THEY INTEND TO USE THE FUNDS RAISED
Key focus is to develop and place our new LLM based device on the market as a B2B2C and in parallel continue the roll out of our existing remote therapeutic monitoring product.

Erik Frick

CEO

With over 20 years of experience in banking, e-commerce, and life science, Erik Frick is a passionate change leader. Currently the CEO of Paindrainer AB with previous experience from Resurs Bank, working as COO and deputy CEO leading a unit supporting all commercial growth in the group.

Prior to that Erik has been board member at Kivra OY as well as sales manager at CDON. Core competences include business development, strategic growth, organizational development, project management, and M&A processes.

erik.frick@paindrainer.com

Carl Borrebaeck

Chairman of the board

Carl Borrebaeck is a professor at the Department of Immunotechnology and chairman of the CREATE Health translational cancer research center at Lund University.

He is an entrepreneur and founder of Paindrainer, SenzaGen AB, Immunovia AB, Alligator Bioscience AB and BioInvent AB. He is also a member of the Royal Swedish Academy of Engineering Sciences (IVA) and former vice-chancellor at Lund University.

carl.borrebaeck@paindrainer.com

NOTES

PharmNovo

PharmNovo is a clinical stage drug development company with our lead candidate PN4047 ready to move forward into the phase IIa PoC study in the first indication, neuropathic pain, by Q2 2026. PN6047 is a novel DORA (delta opioid receptor agonist) which is very selective for the delta receptor and thus does not touch the mu receptor which is responsible for the side effects associated with conventional opioids. PN6047 is potent in reducing neuropathic pain in animal models and safe and tolerable in both animal testing as well as in the phase I first-in-human study.

In phase I, PN6047 was safe and tolerable at an exposure level well above what is predicted to be effective. PN6047 also has potential in several other high value indications such as migraine, opioid withdrawal syndrome (OWS) / opioid use disorder (OUD) and chronic cough. We have patent protection in all major markets until 2041 including the expected extension.

pharmnovo.com

FIELD
Pharmaceuticals

DATE OF INCORPORATION
2007

STOCK MARKET LISTING
No

MATURITY
Phase II ready

PRODUCT ON THE MARKET?
Ready to move forward to the first phase IIa PoC study to demonstrate effect in humans for our promising candidate

AMOUNT THEY WISH TO RAISE WITH MVIP
120 MSEK (Q4 2025) + 180 MSEK (Q2 2026) = 300 MSEK

HOW THEY INTEND TO USE THE FUNDS RAISED
Raising 120 MSEK will finance the first PoC study and raising the additional 180 MSEK will finance an additional 1-2 PoC studies. Raising a total of 300 MSEK will finance 2-3 PoC studies and important value creating, front-loading activities to pave the way for a Pharma taker, e.g long-term tax and DDI studies

Per von Mentzer
CEO

Per is a highly experienced executive with over 30 years in senior leadership roles across international corporations and diverse industries. He has successfully driven business development, transformation, and M&A, building profitable and resilient companies in competitive markets.

Formerly CEO of Elfa International AB and with six years at PharmNovo, he brings extensive expertise in strategic planning, operational excellence, and organizational culture. As CEO of PharmNovo, Per's commercial leadership and broad experience position the company for continued growth and future pharma partnerships.

per.von.mentzer@pharmnovo.com

Jesper Kjerulff
COO and Project Lead

Jesper is a seasoned pharmaceutical executive with more than 20 years' experience directing global, cross-functional teams. At Lundbeck, he led the development of vortioxetine from pre-clinical stage to worldwide approval and launch across the EU, US, China, and Japan.

He brings deep expertise in regulatory interactions with EMA, FDA, and other agencies, alongside significant experience in licensing, co-development, and partnership governance. As COO and Project Lead for PN6047, Jesper drives value creation, strategic risk management, and long-term project success.

jesper.kjerulff@pharmnovo.com

NOTES

Respiratorius

VAL001 is a proprietary dual-release valproic acid formulation designed to optimize HDAC inhibition and boost anti-cancer activity in DLBCL through epigenetic priming. It has demonstrated strong clinical promise, with Phase I/IIa data showing an estimated >80% relative risk reduction.

A successful Phase I PK study confirms the performance of the novel formulation. Recent validation by over 100 physicians shows strong willingness to prescribe, driven by VAL001's ease of use, safety, and unique mechanism—particularly appealing for intermediate and high-risk DLBCL patients.

respiratorius.com

FIELD
Pharmaceutical

DATE OF INCORPORATION
1999

STOCK MARKET LISTING
Yes – Spotlight Stock Market

MATURITY
Growth/clinical stage

PRODUCT ON THE MARKET?
Marketing approval in 2029 after a phase III study

AMOUNT THEY WISH TO RAISE WITH MVIP
To be decided with the financial consortium

HOW THEY INTEND TO USE THE FUNDS RAISED
Forming a financial consortium to engage mid-size and specialty pharma

Johan Drott

CEO and Board Member

Johan brings extensive leadership experience from senior roles in both medical device and pharmaceutical companies, with a strong focus on research, business development, and the commercialization of scientific innovations.

He successfully negotiated a pivotal agreement for Diaprost AB with a top 10 global pharmaceutical company with an option exercised in 2019. Further to this secured a licensing deal with an Australian pharmaceutical firm in 2021.

johan.drott@respiratorius.com

Mia Lundblad

Board Member

Mia has broad experience across pharmaceutical R&D, project management, and business development, holding leadership positions at Novo Nordisk, Ferring Pharmaceuticals, and Respiratorius.

She currently serves as Clinical Pharmacology Scientific Director at Novo Nordisk and was previously CEO of Arcede Pharma.

mia.lundblad@respiratorius.com

NOTES

Reccan

Reccan is a young medtech company dedicated to improving the prognosis for patients diagnosed with pancreatic cancer. Our vision is to set a standard for early detection of pancreatic cancer and therefore save lives.

We are working to change the trajectory of pancreatic cancer mortality by finding the cancer at an earlier stage than is possible today. Early detection makes interventions and treatments more effective. We are developing an easy-to-use blood test for early detection of pancreatic cancer. It is highly accurate, non-invasive, and accessible to all physicians in medical care to detect or exclude the presence of pancreatic cancer.

reccandiagnostics.com

FIELD
Diagnostics

DATE OF INCORPORATION
2014

STOCK MARKET LISTING
No

MATURITY
Clinical stage

PRODUCT ON THE MARKET?
We will have a product/candidate ready for CE-mark within the next 12 months

AMOUNT THEY WISH TO RAISE WITH MVIP
20-40 MSEK

HOW THEY INTEND TO USE THE FUNDS RAISED
To support initial work for European launch

Anna Broden
CEO

Anna has over 20 years of experience in pharma and MedTech, including roles at HemoCue, Allergan, and Ferring. As CEO of Reccan AB, she has successfully led the company through early-stage growth, secured EU Horizon funding and private investments, driving the company through clinical validation and regulatory preparation.

Anna brings deep expertise in business development, quality, and regulatory affairs, with a strong focus on turning innovation into scalable healthcare solutions.

anna.broden@reccandiagnostics.com

Professor Roland Andersson
Founder

Roland is a globally recognized expert in pancreatic cancer and hepatobiliary surgery. As co-founder and Chief Scientific Officer of Reccan AB, he brings decades of clinical and research leadership. His clinical network and scientific credibility are key drivers of the company's success.

roland.andersson@med.lu.se

NOTES

Strike Pharma

Strike Pharma has developed a technology platform that enables the selective delivery of drugs, enclosed in nanoparticles, to specific cells in the body. With this innovation, immune cells can be reprogrammed inside the body (in vivo), which would offer significant advantages to current therapies.

This approach supports the development of next-generation in vivo CAR-T therapies – an advanced form of immunotherapy where a patient's T cells (a type of immune cells) are reprogrammed to recognize and eliminate harmful cells.

Currently, Strike Pharma is developing a drug candidate that reprograms T cells to attack B cells, aiming to improve treatments for autoimmune diseases and cancer.

strikepharma.com

FIELD
Pharma/Biotech

DATE OF INCORPORATION
2020

STOCK MARKET LISTING
No

MATURITY
Preclinical Research

PRODUCT ON THE MARKET?
Preclinical development

AMOUNT THEY WISH TO RAISE WITH MVIP
100 MSEK over 3 years

HOW THEY INTEND TO USE THE FUNDS RAISED
To demonstrate proof of concept in preclinical models and to advance its proprietary drug candidate to clinical phase 0

PHARMA BIOTECH

Per Norlén
CEO

Per Norlén, M.D., PhD, is board certified in clinical pharmacology and with extensive research experience within experimental pharmacology where he holds an associate professorship from Lund University. Norlén is an experienced executive with +20 years of experience of clinical drug development from hospital-based units, big pharma and biotechnology companies.

The last 15 years have been spent in executive leadership teams, as chief medical officer or chief executive officer. Since 2015 he has been chief executive officer at Alligator Bioscience, Targinta, Evaxion Biotech, WntResearch before joining Strike Pharma.

per.norlen@strikepharma.com

NOTES

Suturion

Suturion AB is a pioneering MedTech company based in Lund, Sweden, founded in 2018 by surgeon Gabriel Börner.

The company's groundbreaking innovation, SutureTOOL™, enables a standardized, efficient, and safe closure of the abdominal wall after open surgery. By empowering surgeons to perform fascia closure with precision, it significantly reduces the risk of post-operative complications while delivering substantial time and cost savings for healthcare systems.

suturion.com

FIELD
Medtech

DATE OF INCORPORATION
2018

STOCK MARKET LISTING
No

MATURITY
Expansion commercial stage

PRODUCT ON THE MARKET?
We currently have a product/candidate on the market

AMOUNT THEY WISH TO RAISE WITH MVIP
30-40 MSEK

HOW THEY INTEND TO USE THE FUNDS RAISED
To accelerate our global launch, as well as fund quality improvements in our production

MEDTECH

Paan Hermansson
CEO

Paan Hermansson is Suturion's CEO with close to 25 years of experience in the Medtech industry, having held several leadership positions in both sales and marketing. With a background in economics from Lund University, he has a proven track record of building highly effective and motivated teams, enabling individuals to reach their full potential.

His international experience has provided a deep understanding of cultural differences and the complexities of various healthcare systems and their respective drivers. He has also developed a wide network of industry partners and key opinion leaders in different surgical specialties. In his spare time, Paan enjoys cycling, spending time with his two sons and wife as well as being in the outdoors.

paan.hermansson@suturion.com

Gabriel Börner
Founder, Chief Medical Officer

Gabriel Börner is the founder and Chief Medical Officer of Suturion. He is also currently pursuing a PhD at Lund University. He holds a medical degree from Uppsala University and has been a consultant surgeon at the Trauma & Emergency team at Helsingborg Hospital since 2015.

With numerous accolades including the Hans Jeekel Award (2022) and a role as a surgeon expert in public procurement, Gabriel brings deep clinical expertise and a passion for innovation in healthcare. Outside of work, he enjoys endurance sports, composing music, and gardening. His personal motto is "If it doesn't work today, it might work tomorrow".

gabriel.borner@suturion.com

NOTES

Targinta

Targinta is a preclinical-stage biotech company developing first-in-class Antibody Drug Conjugates (ADCs) and function-blocking antibodies, aimed at the novel cancer target integrin α10β1. Our lead candidates TARG9 and TARG10 both demonstrated strong inhibition of tumor growth and metastasis in preclinical models of aggressive and difficult-to-treat cancer forms including triple negative breast cancer and glioblastoma.

This highly selective and unique targeting shows promise for a disruptive role of TARG9 and TARG10 in immuno-oncology. Patents protect both Targinta's target and lead candidates in antibody-based cancer therapy and diagnostics.

targinta.se

FIELD
Pharmaceutical

DATE OF INCORPORATION
2018

STOCK MARKET LISTING
Targinta is a wholly-owned subsidiary of the listed company Xintela

MATURITY
Preclinical research

PRODUCT ON THE MARKET?
Goal to partner and/or out-license candidate drugs within 2 years

AMOUNT THEY WISH TO RAISE WITH MVIP
50-60 MSEK

HOW THEY INTEND TO USE THE FUNDS RAISED
Complete preclinical studies including toxicology, manufacture and prepare first candidate drug for clinical development

Evy Lundgren-Åkerlund
CEO

Founder of Targinta and Xintela. Extensive experience in biomedical R&D, financing and development of start-up biotech companies. Has taken Xintela's stem cell product XSTEM from idea to completed clinical Phase I/IIa studies.

Previously held senior positions in both academia and industry: CEO/CSO Cartela 2000-2007; CEO Lund Life Science Incubator 2008-2012; CEO of Xintela since 2009 and CSO 2009-2023. Raised over 500 MSEK in equity financing.

evy@xintela.se

NOTES

Bengt Julander
Chairman at Linc AB

Bengt Julander is the Chairman and founder of the publicly listed investment company Linc, considered one of Sweden's most renowned investors in Life Science. He has had a long career in the pharmaceutical industry and co-founded Calliditas Therapeutics – a company recently sold for approximately SEK 12 billion.

Under Julander's leadership, Linc has built a strong portfolio of life science companies. He is known for his deep industry knowledge and successful investments that drive the development of new treatments.

linc.se

Erika Henriksson
Partner at EQT

Erika Henriksson is a partner at the private equity firm EQT, responsible for investments in life science and healthcare across Europe. She has been with EQT since 2007 and has played a key role in the firm's journey to becoming one of the largest private equity firms in the world.

Over the years, she has been involved in several EQT investments, including Karo Healthcare and the buyout of Recipharm from Nasdaq. Erika has a background in corporate finance at SEB Enskilda and holds a degree in business from the Stockholm School of Economics. Her long experience and strategic expertise make her a prominent healthcare investor.

eqtgroup.com

Elin Almstedt
Principal at Navigare Ventures

Elin Almstedt is a Principal at Navigare Ventures – the Wallenberg family's venture investment firm focused on Life Science. She is a prominent investor with experience in both the pharmaceutical industry (e.g., Sobi) and innovation support (as a business coach at Karolinska Institutet Innovations).

At Navigare Ventures, she leads investments in promising startups across the Life Science spectrum. Elin holds a Master's in Medical Science and a PhD in Neuro-oncology from Uppsala University, giving her a unique combination of scientific and commercial expertise.

navigareventures.com

Hugo Mörse
Partner at Bonit Capital and Managing Director of Leksell Social Ventures

Hugo Mörse is a partner at Bonit Capital and Managing Director of Leksell Social Ventures, through which the Leksell family invests its capital. The Leksell family, known for founding the medical technology company Elekta, is among Sweden's most respected players in Life Science.

Hugo leads the family's investments both commercially (via Bonit Capital) and socially (via Leksell Social Ventures). With significant resources behind him, he focuses on supporting innovative companies and projects in the health sector, in line with his long-term commitment to medical advancement and societal benefit.

bonitcapital.com ***leksellsocialventures.com***

Christer Fåhræus

Partner and CEO at Fåhraeus Startup and Growth

Christer Fåhraeus is a serial entrepreneur and the founder and General Partner of Fåhraeus Startup & Growth (FSG), a venture fund focused on early-stage life science and tech companies. He has over thirty years of experience building and leading high-growth ventures in these sectors. Fåhraeus founded and scaled multiple successful companies, including the medtech innovator CellaVision and the generic pharmaceutical firm EQL Pharma – both of which later went public.

In addition to leading FSG's investments, he has held numerous board and executive roles. Fåhraeus combination of deep scientific training (Ph.D. in neurophysiology) and entrepreneurial success makes him a prominent figure in Scandinavian life science innovation and venture investing.

fsg.vc

Maria Tell

COO / Investment Director at Segulah Medical Acceleration

Maria Tell is COO and Investment Director at Segulah Medical Acceleration – Segulah's specialized investment platform in Life Science. With approximately 20 years of experience in investments and business development in medtech and biotech, she brings both strategic and operational expertise.

She has previously worked at GE Healthcare Life Sciences, served as Investment Manager at Almi Invest, and was Marketing Director at the medtech company SyntheticMR – experience that has given her a broad industry perspective. At Segulah Medical, she leads investments in promising medical innovations and supports portfolio companies in accelerating their market development.

segulahmedical.com

THE MVIP INVESTORS

Lovisa Backemar

Principal at Eir Ventures

Lovisa Backemar is a partner at Eir Ventures, a venture capital fund investing in Life Science. She is a medical doctor with a PhD in clinical epidemiology from Karolinska Institutet. Lovisa has also worked as a management consultant at Boston Consulting Group, focusing on strategic projects in the pharmaceutical and healthcare sectors.

Since joining Eir Ventures in 2023, she has played a central role in the team, where her combination of medical and analytical expertise contributes to identifying and supporting innovative Life Science companies.

eirventures.eu

Sebastian Hodel

CEO and CIO at Gainbridge Capital

Sebastian Hodel Fryzell is Managing Partner at Gainbridge Capital Partners, an active investor focusing on entrepreneur-led growth companies. Sebastian has a technical background and over ten years of experience in the financial industry, including as COO of one of Sweden's leading corporate finance advisors.

He brings extensive experience as both an active investor and entrepreneur and has participated in over a hundred transactions as an advisor to growth companies, especially within Life Science.

gainbridge.se

Andreas Grape

CEO and Co-founder at Nordic Angels

Andreas Grape is co-founder and CEO of Nordic Angels, the Nordic region's largest angel investor network. He has been a driving force in Stockholm's startup ecosystem for over 20 years and previously founded the consultancy firm One Agency, which was sold in 2021.

As an active angel investor and advisor, he provides valuable guidance to large parts of Sweden's startup sector. Through Nordic Angels, he has created a platform where investors collaborate with high trust and mobilize capital for promising startups – an initiative that has established the network as a key player in early-stage funding in the region.

nordicangels.com

Ann-Charlotte Beckman

Co-founder at Life Science Invest

Ann-Charlotte Beckman is a serial entrepreneur and investor with over 30 years of experience in Life Science. Among other achievements, she helped launch Viagra in Sweden, served as CEO of Netdoktor (sold to Bonnier), and built up Bonnier Healthcare.

Ann-Charlotte is also the founder of Life Science Invest – a network of over 100 angel investors focused on early-stage Nordic companies in digital health, pharmaceuticals, and medtech. She holds several board positions and is a recurring figure in the HealthTech investment landscape.

lifescienceinvest.se

THE MVIP INVESTORS

Johan Kördel

Managing Partner at Sound Bioventures

Johan Kördel is Co-founder and Managing Partner at Sound Bioventures, a venture fund investing in private pharmaceutical companies. He has over two decades of experience in the pharmaceutical industry and was a co-founder of Biovitrum (now Sobi), where he led business development and research.

Johan also spent ten years at Pharmacia, navigating several major mergers, which gave him deep industry insight. Prior to Sound Bioventures, he served as a Senior Partner at Lundbeckfonden Ventures for twelve years, where he invested in and served on the boards of several successful biotech companies. His combination of scientific expertise (Ph.D.) and investment success makes him a prominent figure in Life Science investing.

soundbioventures.com

This autumn edition marks the inaugural launch of MVIP, with the intention of holding the initiative 1-2 times a year going forward.

If you are a company or investor interested in participating in future editions, please don't hesitate to contact Sarah Lidé (sarah.lide@mediconvillage.se) or Francesco Bez (francesco.bez@mediconvillage.se).

STRATEGIC CAPITAL.
EXPERT GUIDANCE.
LIFE-CHANGING LIFE SCIENCE.

MEDICON
VILLAGE